Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled, Double-blind, Multicenter, Phase III Clinical Study to Compare Efficacy and Safety of Abivertinib Maleate Versus First-line Standard Therapy EGFR-TKI in Patients With Advanced NSCLC With Sensitive EGFR Mutation

Next Previous
Trial Profile

A Randomized Controlled, Double-blind, Multicenter, Phase III Clinical Study to Compare Efficacy and Safety of Abivertinib Maleate Versus First-line Standard Therapy EGFR-TKI in Patients With Advanced NSCLC With Sensitive EGFR Mutation

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abivertinib (Primary) ; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Hangzhou ACEA Pharmaceutical Research

Most Recent Events

  • 12 Nov 2021 Status changed from not yet recruiting to recruiting according to Sorrento Therapeutics media release
  • 12 Nov 2021 According to Sorrento Therapeutics media release, results from this trial published in the journal Clinical Cancer Research
  • 12 Nov 2021 Results (n=227) published in the Sorrento Therapeutics Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top